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Would a carpenter be asked to man-age building a new housing develop-ment?  Probably not. More likely, a 
real estate developer with the skills, experience 
and knowledge of the local market and trades, 
including carpentry, would manage such an 
undertaking. Good developers anticipate and 
address the challenges of building and sell-
ing homes. Delivering attractive, appropriately 
priced homes on time and on budget requires 
that developers use their knowledge, experi-
ence, and judgment to make numerous deci-
sions that engage the right talent at the right time 
to balance development risks and costs. 
Likewise, would musicians form an orches-
tra without a conductor?  Again, probably not. 
Despite the considerable skills of even the very 
best musicians, they collectively create their 
best music when guided by a conductor. 
If real estate developers and orchestra con-
ductors are needed to facilitate their respec-
tive resources to get the best outcomes, why is 
the complex process of translational medical 
research in academia often led by a person with 
deep expertise in only one of, or at best a few 
of, the disciplines required to create viable solu-
tions to important unmet medical needs?
Usually, the responsibility for managing 
translational research in an academic setting 
falls to a researcher designated as the “Principle 
Investigator” (PI).  Academic healthcare institu-
tions are very familiar with the role of PI as the 
responsible party for the conduct of all aspects 
of basic or applied research. A PI may be techni-
cally oriented and conceive of novel solutions, 
or be clinically oriented, with the savvy and 
commitment to appreciate the possible impact 
and champion the implementation of an innova-
tion.  Some PI’s can do both and some can also 
raise venture funds and start a business, but they 
are the exceptions. 
The traditional role of most PIs may not be 
ideal for translational research.  Unlike the rig-
orous training they obtained in their specific 
discipline, PIs typically learn to conduct trans-
lational research by trial and error, inevitably 
making mistakes and experiencing failures along 
the way. Many failures are due to avoidable mis-
takes, such as not anticipating the potential con-
sequences of decisions. Others result from the 
PI relying too heavily on his or her own, often 
limited experience. It is unusual for a PI to even 
consider taking work in a direction outside of 
their area of expertise if a major roadblock is 
encountered mid-stream. As the saying goes, 
“when the only tool you have is a hammer, 
everything looks like a nail.” 
In contrast to the traditional approach, one 
strategy for overcoming the challenges in trans-
lational medical research can be adapted from 
the approaches taken by the successful develop-
er and conductor: focusing responsibility on an 
experienced coach or facilitator.  The facilitator’s 
role is to synergize, harmonize and synchronize 
the work of diverse professionals to achieve 
a shared vision of success through a journey 
with multiple, inter-related steps.  This strategy 
should be even more valuable in translational 
medical research due to its complexity.  It inher-
ently entails more unknowns and risks, as well 
as unique requirements, such as adherence to 
strict constraints to protect animals from undue 
suffering or patients from harm. Even more than 
their counterparts on a housing project or in 
an orchestra, academic researchers often have 
very different motivations that can vary with the 
stage of their career, personal objectives and/
or their institutional policies. In addition, while 
all industries are highly competitive, healthcare 
related businesses today face particularly dif-
ficult dynamic competitive and regulatory envi-
ronments.
For over 15 years, the Consortia for Improving 
Medicine with Innovation and Technology 
(CIMIT) has learned, in essence, how to be the 
equivalent of a developer or conductor to cre-
ate solutions to pressing unmet medical needs. 
CIMIT has learned to orchestrate the isolated 
pockets of expertise and misaligned incentives 
that impede translational research within aca-
demic medical centers to accelerate innovations 
to patient care.
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CIMIT is a consortium of 13 academic medical centers 
and universities in the greater Boston area with a growing 
network of national and international affiliates. CIMIT focus-
es on products, procedures, and clinical systems (see www.
cimit.org.) It has supported the development of more than 
250 potential solutions to important unmet needs through 
over 600 peer-reviewed projects.  After identifying an impor-
tant unmet medical need—perhaps the most critical of all 
starting points—CIMIT funds and facilitates teams through 
the challenging journey that comprises the innovation pro-
cess.  CIMIT has achieved what we believe to be an enviable 
success rate, particularly given that its support starts at the 
very early stages of development: more than 17% of CIMIT-
supported teams have brought solutions to patient care and 
an overlapping 27% have transitioned to commercial part-
ners, with most of the remaining teams still active. 
CIMIT has termed the process of creating innovative 
products, procedures, and care delivery systems as the 
“Healthcare Innovation Cycle.”  (Figure 1) Representing this 
process as cyclical rather than linear highlights a key lesson 
learned: start with clinical problems rather than technology 
solutions and keep a focus on the result of improving patient 
care. While the steps in the process are clean and neat in the-
ory, the cycle is very difficult to implement in practice, even 
with considerable expertise. Many mistakes occur during the 
innovation process causing promising ideas to fail needlessly. 
For example, to share an insight or discovery with the 
world, a PI may describe results in an abstract or present them 
at a conference before properly protecting the underlying 
intellectual property (IP).  While disseminating new knowl-
edge is aligned with academic objectives, it needs to be coor-
dinated with the commercial imperative to protect IP so that 
an economically motivated company or venture capitalist will 
be willing to invest. Further, many PIs have the misperception 
that a patent gives them broad rights to the invention it covers, 
whereas it only gives them the right to preclude others from 
using it.  This possibly subtle distinction has huge potential 
ramifications– if decisions are made such that an invention 
requires the use of IP owned by others to work (i.e., no “free-
dom to operate” or “FTO”), investors will likely not even con-
sider it unless a very robust license agreement is in place with 
those who control the other IP.
Unlike the immediate bad outcome if there is poor coor-
dination between an electrician and a framer in building a 
house, an error in the healthcare innovation cycle may not 
come to light for years, wasting time and money.  Even worse, 
the ramifications of a mistake may never be seen or appreci-
ated by the responsible group, making “learning by doing” 
inefficient and arguably impractical. For example, in the case 
that IP is lost or there is no clean FTO, most investors will not 
even consider the opportunity. The team may only be told that 
an investor was “not interested”, but never know the reason.
The core approach behind the CIMIT Model is to find, 
fund, and facilitate multi-disciplinary teams through the 
innovation cycle to speed and maximize the impact of an 
innovation on patient care. The fact that CIMIT is multi-
institutional increases the opportunities to access the ideal 
experts as team members.  Like a developer or conductor, 
CIMIT facilitators enable team members to focus on what 
they do well in contributing to the process.  
Effective facilitation is not cheap.  It requires seasoned 
individuals with considerable experience who are seen by 
PIs as peers, at least. It also requires that the facilitators allo-
cate the time needed to be actively involved in the project. 
Assigning junior people to manage a portfolio of projects is 
not sufficient. CIMIT facilitators usually commit at least 25% 
and often more than 50% effort to a single project. Just as an 
orchestra with world-class musicians invests in a world-class 
conductor, CIMIT has shown that it is a very good investment 
to engage a team of skilled facilitator to make the most of the 
available resources and teams.
The facilitator must understand and manage the different 
motivations and incentives that exist among members of the 
research teams.  Clinicians are likely to focus on issues that 
most affect the care they can provide to their own patients, 
whereas scientists and technologists may value the potential 
novelty of solutions and entrepreneurs motivated by profit 
potential. Rather than try to change existing motivations or 
incentives, an experienced facilitator can chart a path and 
show team members it aligns multiple objectives in such a 
way to meet everyone’s needs and interests over time.  Success 
requires constantly synchronizing the skills and composition 
of the team to meet the challenges at any point in the process, 
much like the accomplished developer and conductor.  
Figure 1: typical issues encountered in the Healthcare innovation Cycle 
The Cycle begins with a stakeholder, who may be a clinician, patient, 
administrator, supplier, or other participant, observing how care is actually 
delivered – the actual standard of care. From that observation, the individual 
can describe challenges to address and/or opportunities available to improve 
care. Inventors create potential solutions and attempt to demonstrate 
the feasibility of the underlying principles.  Information on challenges 
and opportunities can also inform basic science and the development of 
enabling technologies that can later be incorporated into proposed solutions.  
Robust prototypes are then developed and tested to determine whether 
the solution will create sufficient value under practical considerations and 
constraints to attract commercial investment in a product or service, or a 
healthcare provider to implement a new procedure. Evidence is gathered to 
demonstrate that the product, service or procedure enables a “best practice” 
that should be replicated.  At that point, the work is still not completed; 
the solution needs to be broadly disseminated and made widely available 
before it can become the new standard of care.  When the cycle operates at 
its best, it is indeed a spiral, arriving at the end of each rotation at a higher 
standard of care, awaiting future medical insights and innovations for further 
enhancement.
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However, whereas a successful developer or conductor 
generally receives the acclaim for their work, the credit for 
success of the healthcare innovation goes to the research 
team and especially the designated PIs, not the individuals 
who facilitate the cycle.  Therefore, finding people with the 
required skills and experience who are willing to facilitate 
the success of others can be a significant challenge. Further, 
finding sources of funding that understand the value that such 
facilitation brings is a challenge. Fortunately, the situation is 
changing in part due CIMIT’s track record of success and that 
of organizations adapting and using the CIMIT Model.
Substantial institutional investment is initially required 
to put the CIMIT model in place, including support for the 
facilitation team and seed grant funding to attract innovators 
and clinician researchers. CIMIT has documented its clinical, 
academic and commercial metrics of success to understand 
and improve the short and long-term value of the investment. 
In looking at just the financial return to member institu-
tions, within a few years their investment is more than fully 
repaid through grants and associated overhead, with further 
downstream financial return in licensing fees and royalties. 
Since CIMIT entered a steady state, for every dollar CIMIT 
institutions invest in the infrastructure of CIMIT, they receive 
$3.50 directly back from CIMIT that year to fund potential 
solutions. In addition, each dollar of CIMIT-funded projects 
results in an additional $10 of funding to the institutions 
from outside sources, usually at full indirect cost. The result 
is more than a 35:1 multiplier of funds to advance solutions 
initiated with CIMIT support.  Commercial investments are 
in addition and are of similar magnitude, and may generate 
licensing and royalty payments. 
We conclude that translational medical research can be 
significantly enhanced through active facilitation and treat-
ing it as a learnable, dynamic process. It is enhanced by hav-
ing the flexibility to assemble the most appropriate teams 
from many organizations to address the specific demands of 
a potential solution in each stage of its development.  While 
some contend that academic institutions should eschew 
steps in the innovation cycle beyond pure discovery, we 
believe this approach is too wasteful of excellent clinical 
observations that would otherwise never lead to advance-
ments in patient care.  In fact, the CIMIT model imbeds busi-
ness expertise throughout the innovation cycle. 
 The CIMIT Model works well in the resource-rich environ-
ment in Boston. It has also been shown to work well elsewhere 
when adapted, such as in Manchester, United Kingdom, and 
Singapore (ref IEEE article).  It has the potential to create even 
more impact as the CIMIT network expands, linking medical 
innovation hubs across the world to enable enhanced access 
to assemble the best teams to address the ever-present criti-
cal challenges of improving patient care.  Recent expansion 
of CIMIT’s scope to develop pharmacological solutions will 
reveal whether the same applies to therapeutics.
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